GLAXO WELLCOME IMITREX U.S. SALES GROW 146% IN FIRST HALF TO $270.8 MIL.; CONTRACT SALES FORCE WILL BOOST PROMOTION OF CEFTIN, FLONASE, WELLBUTRIN
Executive Summary
U.S. sales of Glaxo Wellcome's migraine therapy Imitrex jumped 146% in the first half of 1996, CEO Richard Sykes told analysts in New York City Aug. 1. The migraine therapy posted domestic sales of $270.8 mil. ([pound]177 mil.) for the six months.